Abatacept for SLE Arthritis (IM101-330)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 1, 2019

Study Completion Date

September 1, 2019

Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
BIOLOGICAL

abatacept also known as Orencia also known as CTLA4-Ig

125mg injected subcutaneously weekly for 16 weeks

DRUG

Placebo

Trial Locations (2)

90095

UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles

92093

University of California, San Diego, San Diego

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, Los Angeles

OTHER